MLV’s healthcare analyst Arlinda Lee weighed in today with a few insights on MannKind Corporation (NASDAQ:MNKD), after the company reported its fourth-quarter results, posting EPS of ($0.09), which was in-line with MLV’s estimate. The analyst rates the stock a Hold with a $7 price target, in-line with Piper Jaffray’s recommendation, which was also issued today.
Lee noted, “While management was upbeat following the launch of Afrezza in early February, it declined to provide specific guidance and reiterated that financial metrics would not be reflected in the P&L for some time. The Company did shed some light on new potential pipeline assets. We look to NRx and TRx data for Afrezza as well as additional details on new pipeline products to be near-term catalysts for MNKD stock.” The analyst added, “We note that impediments to the uptake of Afrezza include physician re-education and the necessity for prospective patients to make an appointment with a doctor for a pulmonary function test.”
Bottom line, “With limited financial disclosure, investors will be focused on Afrezza NRx and TRx metrics in the near-term. In a few months, we also expect MNKD to provide additional details on its emerging pipeline assets.”
Analyst Arlinda Lee has a total average return of 6.4% and a 50.0% success rate. Lee has a average return when recommending MNKD, and is ranked #1308 out of 3483 analysts, according to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform.